Table 4. Relative sensitivity, specificity and PPV of different tests for the detection of high-grade disease based on 19 CIN3+ cases and 40 CIN2+ cases.
| Test | Sensitivity (95% CI) | Specificity (95% CI) | PPV (%,all) (95% CI) | PPV (%,only for those referred for colposcopy) (95% CI) |
|---|---|---|---|---|
|
BD HPV | ||||
| CIN3+ |
100.0 (82.4–100.0) |
|
2.0 (1.2–3.0) |
16.5 (10.3–24.6) |
| CIN2+ |
97.5 (86.8–99.9) |
84.3 (83.3–85.2) |
4.0 (2.9–5.5) |
33.9 (25.3–43.3) |
|
Roche Cobas | ||||
| CIN3+ |
100.0 (82.4–100.0) |
|
2.0 (1.2–3.1) |
16.7 (10.3–24.8) |
| CIN2+ |
97.5 (86.8–99.9) |
84.5 (83.6–85.4) |
4.1 (2.9–5.5) |
34.2 (25.6–43.7) |
|
Qiagen Hybrid Capture 2 | ||||
| CIN3+ |
100.0 (82.4–100.0) |
|
2.1 (1.3–3.3) |
16.0 (9.9–23.8) |
| CIN2+ |
97.5 (86.8–99.9) |
85.4 (84.5–86.3) |
4.3 (3.1–5.8) |
32.8 (24.4–42.0) |
|
Abbott RealTime High Risk HPV | ||||
| CIN3+ |
94.7 (74.0–99.9) |
|
2.2 (1.3–3.5) |
16.1 (9.8–24.2) |
| CIN2+ |
95.0 (83.1–99.4) |
87.2 (86.3–88.0) |
4.7 (3.4–6.5) |
33.9 (25.3–43.5) |
|
Gen-Probe APTIMA | ||||
| CIN3+ |
100.0 (82.4–100.0) |
|
3.1 (1.9–4.7) |
17.4 (10.8–25.9) |
| CIN2+ |
97.5 (86.8–99.9) |
90.2 (89.5–91.0) |
6.3 (4.5–8.5) |
35.8 (26.8–45.5) |
|
NorChip PreTect HPV-Proofera | ||||
| CIN3+ |
68.8 (41.3–89.0) |
|
3.7 (1.9–6.5) |
20.0 (10.4–33.0) |
| CIN2+ | 71.4 (53.7–85.4) | 95.2 (94.7–95.8) | 8.4 (5.5–12.2) | 45.5 (32.0–59.4) |
Abbreviations: CI=confidence interval; HPV=human papillomavirus.
a
Based on 16 cases of CIN3+ and 35 cases of CIN2+.